Ultromics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
66
- Latest Deal Type
-
Later Stage VC
- Investors
-
16
Ultromics General Information
Description
Developer of an artificial intelligence-based cardiovascular diagnostic technology designed to diagnose coronary heart disease. The company's technology is applied to electrocardiograms to improve the diagnostic accuracy of coronary artery disease, enabling clinicians to make the correct decisions from complex data extracted from electrocardiograms.
Contact Information
Website
www.ultromics.comCorporate Office
- 4630 Kingsgate
- Cascade Way, Oxford Business Park South
- Oxford OX4 2SU
- England, United Kingdom
Corporate Office
- 4630 Kingsgate
- Cascade Way, Oxford Business Park South
- Oxford OX4 2SU
- England, United Kingdom
Ultromics Timeline
Ultromics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 01-Mar-2024 | Completed | Generating Revenue | |||
| 7. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 6. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 5. Early Stage VC (Series B) | 10-Aug-2021 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 15-Jun-2020 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 22-May-2018 | Completed | Generating Revenue | |||
| 2. Seed Round | 19-May-2017 | $2.65M | $2.65M | Completed | Startup | |
| 1. University Spin-Out | 22-Mar-2017 | Completed | Startup |
Ultromics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B Preferred | ||||||||
| Series B Preferred | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| A Ordinary | ||||||||
| Ordinary | 3,333 | $0.000138 | $2.07 | $2.07 | 1x | $2.07 | 0.22% | |
| A Ordinary | 100,000 | $0.000138 | $2.07 | $2.07 | 1x | $2.07 | 6.5% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Ultromics Comparisons
Industry
Financing
Details
Ultromics Competitors (25)
One of Ultromics’s 25 competitors is Corify Care, a Venture Capital-Backed company based in Madrid, Spain.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Corify Care | Venture Capital-Backed | Madrid, Spain | ||||
| Circle Cardiovascular Imaging | Private Equity-Backed | Calgary, Canada | ||||
| SigTuple | Venture Capital-Backed | Bangalore, India | ||||
| Advantis Medical Imaging | Venture Capital-Backed | Eindhoven, Netherlands | ||||
| Caristo Diagnostics | Venture Capital-Backed | Oxford, United Kingdom |
Ultromics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ultromics Patents
Ultromics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202003346-D0 | Neural network | Inactive | 06-Mar-2020 | ||
| GB-202003347-D0 | Neural network | Inactive | 06-Mar-2020 | ||
| US-20230104425-A1 | Assessing heart parameters using neural networks | Active | 06-Mar-2020 | ||
| EP-4114271-A1 | Assessing heart parameters using neural networks | Pending | 06-Mar-2020 | ||
| US-12207968-B2 | Assessing heart parameters using neural networks | Active | 06-Mar-2020 | A61B8/0883 |
Ultromics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ultromics Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| UPMC Enterprises | Corporate Venture Capital | Minority | ||
| Blue Venture Fund | Corporate Venture Capital | Minority | ||
| GV | Corporate Venture Capital | Minority | ||
| Nova Capital (Italy) | Growth/Expansion | Minority | ||
| Optum Ventures | Corporate Venture Capital | Minority |
Ultromics FAQs
-
When was Ultromics founded?
Ultromics was founded in 2017.
-
Where is Ultromics headquartered?
Ultromics is headquartered in Oxford, United Kingdom.
-
What is the size of Ultromics?
Ultromics has 66 total employees.
-
What industry is Ultromics in?
Ultromics’s primary industry is Diagnostic Equipment.
-
Is Ultromics a private or public company?
Ultromics is a Private company.
-
What is Ultromics’s current revenue?
The current revenue for Ultromics is .
-
How much funding has Ultromics raised over time?
Ultromics has raised $71.1M.
-
Who are Ultromics’s investors?
UPMC Enterprises, Blue Venture Fund, GV, Nova Capital (Italy), and Optum Ventures are 5 of 16 investors who have invested in Ultromics.
-
Who are Ultromics’s competitors?
Corify Care, Circle Cardiovascular Imaging, SigTuple, Advantis Medical Imaging, and Caristo Diagnostics are some of the 25 competitors of Ultromics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
